Periprocedural Antiplatelet Management in Hemodialysis
Routine hemodialysis sessions generally do not require stopping chronic antiplatelet therapy solely due to hemodialysis. [1] Antiplatelet interruption is considered only for separate procedures performed around dialysis access (eg, creation or revision of an arteriovenous fistula or graft) when bleeding risk is clinically important. [1], [2]
Medication Selection Algorithm
Medication management is based on the antiplatelet agent and whether a bleeding-risk dialysis access procedure is planned. [1], [2]
- Aspirin (including low-dose aspirin): continuation is generally favored for most procedures when interruption is not required for bleeding control. [1], [3]
- P2Y12 inhibitors (clopidogrel, ticagrelor): interruption is typically considered before procedures with clinically significant bleeding risk. [1], [4]
- P2Y12 inhibitors (prasugrel): interruption is typically considered before procedures with clinically significant bleeding risk. [1], [4]
Key Evidence Supporting This Recommendation
Perioperative antithrombotic guidance from the American College of Chest Physicians recommends continuing aspirin in many contexts rather than routinely stopping aspirin before surgery. [3], [4]
Monotherapy Versus Combination Therapy
Dual antiplatelet therapy interruption decisions are based on thrombotic risk and procedure bleeding risk, not on the dialysis session itself. [1] When dual antiplatelet therapy is required due to recent coronary stenting or other high thrombotic risk, perioperative management should be individualized with cardiology input. [1]
Important Clarifications for Hemodialysis
Antiplatelet cessation should not be automatic before the hemodialysis treatment itself. [1] Clinical focus should be placed on whether hemostasis is required for a distinct dialysis access procedure with meaningful bleeding risk. [1], [2]
Initiation Thresholds and Indications for Holding Therapy
Holding antiplatelet agents is considered when a separate surgical or procedural intervention with clinically significant bleeding risk is planned. [1], [2]
- Clopidogrel is typically held for 5 days before surgery when interruption is required. [3], [4]
- Ticagrelor is typically held for 3–5 days before surgery when interruption is required. [4]
- Prasugrel is typically held for 7–10 days before surgery when interruption is required. [4]
- Aspirin is often continued when feasible in perioperative management plans for many procedures. [1], [3]
Common Pitfalls to Avoid
Stopping antiplatelet therapy without a planned procedure that increases bleeding risk exposes patients to avoidable thrombotic risk. [1] Assuming that all antiplatelet interruption is driven by hemodialysis timing rather than the bleeding-risk access procedure increases the likelihood of unnecessary discontinuation. [1], [2]
Targets or Goals of Therapy
The goal of management around dialysis access procedures is balancing bleeding risk from the procedure against thrombotic risk from antiplatelet interruption. [1] Continuation of appropriate antiplatelet therapy during routine hemodialysis supports maintenance of cardiovascular secondary prevention while avoiding unnecessary treatment-related discontinuation. [1]